Financial update for the first quarter of 2015

• Cash, cash equivalents and financial instruments of the Company amounted to 59.2 million euros as at March 31, 2015

• Co-development and commercialization agreement with AstraZeneca including an upfront payment of 250 million US dollars, signed in April 2015

Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH) today announced it cash position for the first three months of 2015.

Cash, cash equivalents and financial instruments of the Company amounted to 59.2 million euros as at March 31, 2015. As at same date, the financial liabilities of the Company amounted to 4.1 million euros.

“The signature in April of a partnership with AstraZeneca for IPH2201 marks a milestone in our development. Innate Pharma has now the means to grow towards late stage development and potential commercial stage.” said Hervé Brailly, CEO.

Revenues for the first three months of 2015 amounted to 0.4 million euros (0.6 million euros for the same period in 2014).This revenue is from Innate Pharma’s collaboration and licensing agreement with Bristol-Myers Squibb and largely relates to recognition of the upfront payment of 24.9 million euros (35.3 million dollars) throughout the expected duration of the clinical trials ongoing at the date of signing the agreement (July 2011).

***
Innate Pharma has been selected by EnterNext, part of the Euronext Stock exchange, to become a member of the Tech 40 Index.  This Euronext label is awarded on a yearly basis to the top 40 technology companies listed on the SME’s tier of the Euronext exchange.
***